A5078937401- Pancreatitis Pathology and Treatment
- Gastroesophageal reflux and treatments
- Pancreatic and Hepatic Oncology Research
- Liver Disease Diagnosis and Treatment
- Gastrointestinal motility and disorders
- Nutrition and Health in Aging
- Diabetes Management and Research
- Healthcare cost, quality, practices
- Diabetes Treatment and Management
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Body Composition Measurement Techniques
- Abdominal Trauma and Injuries
- Abdominal Surgery and Complications
- Brain Metastases and Treatment
- Appendicitis Diagnosis and Management
- Clinical Nutrition and Gastroenterology
- Diet and metabolism studies
- Diabetes and associated disorders
- Microscopic Colitis
- Alkaloids: synthesis and pharmacology
Aalborg University
2023-2025
Aalborg University Hospital
2017-2025
Mech-Sense
2021-2025
Hvidovre Hospital
2021
Odense University Hospital
2021
Bispebjerg Hospital
2021
Understanding the nature of inflammatory pancreatic diseases is essential for planning health care system requirements and interventions. The aim this study was to quantify trajectories their association with cancer in a population-based setting.
Emerging evidence suggests that individuals who recover from acute pancreatitis may face a significant risk of mortality during the early post-discharge period. Despite these concerns, comprehensive population-based studies on this issue are lacking. To study in-hospital and in patients with how it has changed over time. In Danish nationwide cohort study, we included all adults discharged after an incident episode between 2002 2017. For each patient, five general population, matched by age...
Dysmotility is common in acute pancreatitis (AP) and may be evaluated using radiopaque markers imaging. We present a simple CT-based approach, which was employed hospitalized patients with AP. This secondary analysis of randomized, controlled trial conducted at four Danish centers. Patients admitted AP systemic inflammatory response syndrome were randomized to receive 5 days intravenous methylnaltrexone or placebo (lactated ringer) added standard management. Self-reported stool frequency...
INTRODUCTION: Opioids used to manage severe pain in acute pancreatitis (AP) might exacerbate the disease through effects on gastrointestinal and immune functions. Methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, may counteract these without changing analgesia. METHODS: This double-blind, randomized, placebo-controlled trial included adult patients with AP systemic inflammatory response syndrome at 4 Danish centers. Patients were randomized receive 5 days of continuous...
Abstract Objective Post-pancreatitis diabetes mellitus (PPDM) is a frequent complication of pancreatitis and associated with an increased risk adverse outcomes. Metformin recommended for the treatment PPDM, but evidence its risk-benefit profile limited. In pharmaco-epidemiologic study, we investigated association between metformin outcomes in patients PPDM. Design Methods Danish nationwide population-based cohort included adults (≥18 years) incident PPDM or type 2 2009 2018. was categorised...
Abstract Opioids change gut motility, and opium tincture has been used for treatment of chronic diarrhoea centuries. However, the effects have never documented in controlled trials. We aimed to investigate on gastrointestinal transit frequency bowel movements, stool consistency, symptoms sedation. Twenty healthy subjects were included this randomized trial. Opium or placebo was each applied 9 days. Gastrointestinal motility investigated with 3D‐transit system. Bowel movements recorded daily....
INTRODUCTION: The purpose of this study was to investigate the risk metabolic sequelae and all-cause mortality in a population-based cohort chronic pancreatitis (CP) patients with without prior acute (AP). METHODS: We used nationwide health registries identify all Danish residents (18 years older) incident CP from 2000 2018. Information on AP/CP diagnoses, (post-pancreatitis diabetes mellitus [PPDM], exocrine pancreatic dysfunction, osteoporosis), were obtained national registries. cases...
Abstract Introduction Pain is the foremost complication of chronic pancreatitis (CP), affecting about 70% patients. However, pathophysiological understanding and management CP-related pain complex, likely as patients have diverse “pain phenotypes” responding differently to treatment. This study aims develop a bedside test panel identify distinct phenotypes, investigate temporal evolution, determine whether they can be used predict treatment response. Method The INPAIN an international,...
Abstract Background Moderate to severe acute pancreatitis (AP) is associated with a high rate of complications and increased mortality, yet no targeted pharmacologic treatment currently exists. As pain dominant symptom in AP, patients are exposed excess levels both endo- exogenous opioids, which may have harmful effects on the course AP. This trial investigates peripherally acting μ-opioid receptor antagonist (PAMORA) methylnaltrexone disease severity clinical outcomes moderate Methods...
Abstract Background Acute and chronic pancreatitis constitute a continuum of inflammatory disease the pancreas with an increasing incidence in most high-income countries. A subset patients history suffer from recurrence acute attacks, which accelerate progression towards end-stage loss exocrine endocrine function. There is currently no available prophylactic treatment for recurrent apart removing risk factors, not always possible. Pain primary symptom pancreatitis, induces endogenous release...
Abstract Background Acute and chronic pancreatitis constitute a continuum of inflammatory disease the pancreas with an increasing incidence in most high-income countries. A subset patients history suffer from recurrence acute attacks, which accelerate progression towards end-stage loss exocrine endocrine function. There is currently no available prophylactic treatment for recurrent apart removing risk factors, not always possible. Pain primary symptom pancreatitis, induces endogenous release...
Abstract Background : Moderate to severe acute pancreatitis (AP) is associated with a high rate of complications and increased mortality, yet no targeted pharmacologic treatment currently exists. As pain dominant symptom in AP, patients are exposed excess levels both endo- exogenous opioids, which may have harmful effects on the course AP. This trial investigates peripherally acting µ-opioid receptor antagonist (PAMORA) methylnaltrexone disease severity clinical outcomes moderate Methods...